On top of that, AP is a remarkable bioactive substance in the treatment of NSCLC, as demonstrated by its ability to inhibit cell proliferation by suppressing promoter expression, inhibit angiogenesis and tumor growth by acting as a HIF-1α inhibitor, reduce metastasis, and induce apoptosis in NSCLC [14,15,16,17]. Here, HIF1A is linked to non-small cell lung carcinoma.